U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition
Go back to U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition| LOGICVISION (NASDAQ: LGVN) | Delayed: 2.49 -0.22 (8.12%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.71 | 52 Week High | $1.62 | |||
| Open | $2.80 | 52 Week Low | $0.35 | |||
| Day High | $2.80 | P/E | N/A | |||
| Day Low | $2.30 | EPS | $-0.17 | |||
| Volume | 526,157 | |||||
